Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.56 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.49 |
| ▸ | CA1 | P00915 | 2/20 | 0.48 |
| ▸ | CA2 | P00918 | 2/20 | 0.48 |
| ▸ | CA12 | O43570 | 1/20 | 0.48 |
| ▸ | CA7 | P43166 | 1/20 | 0.48 |
| ▸ | CA9 | Q16790 | 1/20 | 0.48 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.48 |
| ▸ | KIF11 | P52732 | 3/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | APEX1 | P27695 | 1/20 | 0.44 |
| ▸ | RECQL | P46063 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL8506781 | 0.98 | TAAR1 (0.54) | TAAR1AOC3CA1CA2CA12 | |
| SCHEMBL422025 | 0.84 | RAB9A (0.60) | TAAR1TDP1MAPK1ALDH1A1MAPT | |
| SCHEMBL6562809 | 0.83 | TAAR1 (0.75) | TAAR1LMNAHSD17B10MAPTNPC1 | |
| Hydrochloric Acid SCHEMBL8615621 | 0.82 | KIF11 (0.51) | TAAR1AOC3CA1CA2CA12 | |
| Hydrochloric Acid SCHEMBL6563360 | 0.81 | TAAR1 (0.71) | TAAR1MAPTNPC1RAB9ACYP3A4 | |
| SCHEMBL1465852 | 0.80 | CA1 (0.50) | TAAR1AOC3CA1CA2CA12 | |
| SCHEMBL3436081 | 0.80 | NPC1 (0.60) | AOC3CA1CA2CA12CA7 | |
| SCHEMBL1506598 | 0.80 | CA1 (0.50) | AOC3CA1CA2CA12CA7 | |
| SCHEMBL7295293 | 0.80 | RAB9A (0.69) | CA1CA2MAPK1ALDH1A1LMNA | |
| SCHEMBL5187903 | 0.79 | AOC3 (0.64) | TAAR1AOC3CA1CA2CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 76 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1070048-A4 | CALCILYTIC COMPOUNDS | SMITHKLINE BEECHAM CORP (US) | 2001-11-07 | — | — | EP | claimed |
| EP-1070048-A1 | CALCILYTIC COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2001-01-24 | — | — | EP | claimed |
| WO-1999051569-A1 | CALCILYTIC COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 1999-10-14 | — | — | WO | claimed |
| EP-0901459-A1 | CALCILYTIC COMPOUNDS | NPS PHARMACEUTICALS, INC. (US) | 1999-03-17 | — | — | EP | claimed |
| WO-1997037967-A1 | CALCILYTIC COMPOUNDS | NPS PHARMACEUTICALS, INC. (US) | 1997-10-16 | — | — | WO | claimed |
| CN-110114346-B | Improved process for preparing R-6-hydroxy-8- [ 1-hydroxy-2- [2- (4-methoxyphenyl) -1, 1-dimethylethylaminoethyl ] -2H-1, 4-benzoxazin-3 (4H) -one hydrochloride | INKE股份公司 | 2023-10-31 | — | — | CN | disclosed |
| US-20180111905-A1 | N2-(2-METHOXYPHENYL)PYRIMIDINE DERIVATIVE, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION FOR CANCER PREVENTION OR TREATMENT CONTAINING SAME AS ACTIVE INGREDIENT | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2018-04-26 | — | — | US | disclosed |
| US-20180111905-A1 | N2-(2-METHOXYPHENYL)PYRIMIDINE DERIVATIVE, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION FOR CANCER PREVENTION OR TREATMENT CONTAINING SAME AS ACTIVE INGREDIENT | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2018-04-26 | — | — | US | disclosed |
| WO-2016167511-A2 | N2-(2-METHOXYPHENYL)PYRIMIDINE DERIVATIVE, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION FOR CANCER PREVENTION OR TREATMENT CONTAINING SAME AS ACTIVE INGREDIENT | 한국화학연구원 | 2016-10-20 | — | — | WO | disclosed |
| US-8957089-B2 | Tetrahydroisoquinolines, pharmaceutical compositions containing them, and their use in therapy | AbbVie Deutschland GmbH & Co. KG (DE) | 2015-02-17 | — | — | US | disclosed |
| US-8957089-B2 | Tetrahydroisoquinolines, pharmaceutical compositions containing them, and their use in therapy | AbbVie Deutschland GmbH & Co. KG (DE) | 2015-02-17 | — | — | US | disclosed |
| US-8957089-B2 | Tetrahydroisoquinolines, pharmaceutical compositions containing them, and their use in therapy | AbbVie Deutschland GmbH & Co. KG (DE) | 2015-02-17 | — | — | US | disclosed |
| EP-1112073-A1 | CALCILYTIC COMPOUNDS | SmithKline Beecham Corporation (US) | 2001-07-04 | — | — | EP | disclosed |
| WO-2001008673-A1 | CALCILYTIC COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2001-02-08 | — | — | WO | disclosed |
| WO-2000009132-A1 | CALCILYTIC COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2000-02-24 | — | — | WO | disclosed |
| EP-0973730-A1 | CALCILYTIC COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2000-01-26 | — | — | EP | disclosed |
| EP-0901459-A1 | CALCILYTIC COMPOUNDS | NPS PHARMACEUTICALS, INC. (US) | 1999-03-17 | — | — | EP | disclosed |
| WO-1998045255-A1 | CALCILYTIC COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 1998-10-15 | — | — | WO | disclosed |
| WO-1997037967-A1 | CALCILYTIC COMPOUNDS | NPS PHARMACEUTICALS, INC. (US) | 1997-10-16 | — | — | WO | disclosed |
| US-4581172-A | Substituted pyrimido[6,1-a]isoquinolin-4-ones,pyrimido[6,1-a]benzozepin-4-ones and pyrimido[6,1-a]benzodiazepin-4-ones useful for prevention of thromboses and treating hypertension | HOFFMANN-LA ROCHE INC. (US) | 1986-04-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180111905-A1 | N2-(2-METHOXYPHENYL)PYRIMIDINE DERIVATIVE, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION FOR CANCER PREVENTION OR TREATMENT CONTAINING SAME AS ACTIVE INGREDIENT | ALK, NPM1, EML4 | TAAR1 4670/4885AOC3 4243/4885CA1 4701/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.